Tuberculosis-Spoligo-Rifampin-Isoniazid typing: An all-in-one assay technique for surveillance and control of multidrug-resistant tuberculosis on Luminex devices

Journal of Clinical Microbiology

Volumn 51, Issue 11, 2013, Pages 3527-3534

  Kiréopori Gomgnimbou, Michel ^a,b   Hernandez Neuta, Ivan ^c   Panaiotov, Stefan ^d   Bachiyska, Elizabeta ^d   Carlos Palomino, Juan ^e   Martin, Anandi ^e   Del Portillo, Patricia ^c   Refregier, Guislaine ^a   Sola, Christophe ^a  

^a CNRS   (France)

^b CENTRE MURAZ   (Burkina Faso)

^c Genomics and Evolution of Communities of Environmental Microorganisms   (Colombia)

^d NATIONAL CENTER OF INFECTIOUS AND PARASITIC DISEASES   (Bulgaria)

^e GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAMPICIN;

ACCURACY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIOPHAGE TYPING; BACTERIUM DETECTION; BACTERIUM ISOLATE; CODON; CONTROLLED STUDY; DRUG SENSITIVITY; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; HIGH THROUGHPUT SCREENING; INHA GENE; INTERMETHOD COMPARISON; KATG GENE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RPOB GENE; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS SPOLIGO RIFAMPIN ISONIAZID TYPING;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EPIDEMIOLOGICAL MONITORING; HUMANS; INDIVIDUALIZED MEDICINE; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MOLECULAR EPIDEMIOLOGY; MOLECULAR TYPING; MUTATION, MISSENSE; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84886535731     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01523-13     Document Type: Article

References (46)

1. Nakajima H. 1993. Tuberculosis: a global emergency. World Health Forum 14:438.
2. World Health Organization. 2012. Global tuberculosis report 2012. World Health Organization, Geneva, Switzerland.
3. Brites D, Gagneux S. 2012. Old and new selective pressures on Mycobacterium tuberculosis. Infect. Genet. Evol. 12:678-685.
4. Zager EM, McNerney R. 2008. Multidrug-resistant tuberculosis. BMC Infect. Dis. 8:10.
5. Zar HJ, Udwadia ZF. 2013. Advances in tuberculosis 2011-2012. Thorax 68:283-287.
6. Kapur V, Li LL, Hamrick MR, Plikaytis BB, Shinnick TM, Telenti A, Jacobs WR, Jr, Banerjee A, Cole S, Yuen KY, Claridge JE, Kreiswirth BN, Musser JM. 1995. Rapid Mycobacterium species assignment and unambiguous identification of mutations associated with antimicrobial resistance in Mycobacterium tuberculosis by automated DNA sequencing. Arch. Pathol. Lab. Med. 119:131-138.
7. Kapur V, Li LL, Iordanescu S, Hamrick MR, Wanger A, Kreiswirth BN, Musser JM. 1994. Characterization by automated DNA sequencing of mutations in the gene (rpoB) encoding the RNA polymerase beta subunit in rifampin-resistant Mycobacterium tuberculosis strains from New York City and Texas. J. Clin. Microbiol. 32:1095-1098.
8. Moghazeh SL, Pan X, Arain T, Stover CK, Musser JM, Kreiswirth BN. 1996. Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Antimicrob. Agents Chemother. 40:2655-2657.
9. Musser JM. 1995. Antimicrobial agent resistance in mycobacteria: molecular genetic insight. Clin. Microbiol. Rev. 8:496-514.
10. Musser JM, Kapur V, Williams DL, Kreiswirth BN, van Soolingen D, van Embden JD. 1996. Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance. J. Infect. Dis. 173:196-202.
11. Telenti A, Imboden P, Marchesi F, Schmidheini T, Bodmer T. 1993. Direct, automated detection of rifampin-resistant Mycobacterium tuberculosis by polymerase chain reaction and single-strand conformation polymorphism analysis. Antimicrob. Agents Chemother. 37:2054-2058.
12. Zhang Y, Heym B, Allen B, Young D, Cole S. 1992. The catalaseperoxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 358:591-593.
13. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, Gler MT, Blakemore R, Worodria W, Gray C, Huang L, Caceres T, Mehdiyev R, Raymond L, Whitelaw A, Sagadevan K, Alexander H, Albert H, Cobelens F, Cox H, Alland D, Perkins MD. 2011. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 377:1495-1505.
14. De Beenhouwer H, Lhiang Z, Jannes G, Mijs W, Machtelinckx L, Rossau R, Traore H, Portaels F. 1995. Rapid detection of rifampin resistance in sputum and biopsy specimens from tuberculosis patients by PCR and line probe assay. Tuber. Lung Dis. 76:425-430.
15. Hillemann D, Rusch-Gerdes S, Richter E. 2007. Evaluation of the Geno- Type MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J. Clin. Microbiol. 45:2635-2640.
16. Feuerriegel S, Oberhauser B, George AG, Dafae F, Richter E, Rusch- Gerdes S, Niemann S. 2012. Sequence analysis for detection of first-line drug resistance in Mycobacterium tuberculosis strains from a highincidence setting. BMC Microbiol. 12:90.
17. Hernandez-Neuta I, Varela A, Martin A, von Groll A, Jureen P, Lopez B, Imperiale B, Skenders G, Ritacco V, Hoffner S, Morcillo N, Palomino JC, Del Portillo P. 2010. Rifampin-isoniazid oligonucleotide typing: an alternative format for rapid detection of multidrug-resistant Mycobacterium tuberculosis. J. Clin. Microbiol. 48:4386-4391.
18. Colovai AI, Vasilescu ER, Foca-Rodi A, Kim-Schulze S, Hussaini N, D'Agati DV, Markowitz GS, Wang C, Cohen DJ, Hardy MA, Suciu- Foca N. 2005. Acute and hyperacute humoral rejection in kidney allograft recipients treated with anti-human thymocyte antibodies. Hum. Immunol. 66:501-512.
19. Ocheretina O, Merveille YM, Mabou MM, Escuyer VE, Dunbar SA, Johnson WD, Pape JW, Fitzgerald DW. 2013. Use of Luminex MagPlex magnetic microspheres for high-throughput spoligotyping of Mycobacterium tuberculosis isolates in Port-Au-Prince, Haiti. J. Clin. Microbiol. 51: 2232-2237.
20. Fabre L, Zhang J, Guigon G, Le Hello S, Guibert V, Accou-Demartin M, de Romans S, Lim C, Roux C, Passet V, Diancourt L, Guibourdenche M, Issenhuth-Jeanjean S, Achtman M, Brisse S, Sola C, Weill FX. 2012. CRISPR typing and subtyping for improved laboratory surveillance of Salmonella infections. PLoS One 7:e36995. doi:10.1371/journal.pone .0036995.
21. Ginevra C, Jacotin N, Diancourt L, Guigon G, Arquilliere R, Meugnier H, Descours G, Vandenesch F, Etienne J, Lina G, Caro V, Jarraud S. 2012. Legionella pneumophila sequence type 1/Paris pulsotype subtyping by spoligotyping. J. Clin. Microbiol. 50:696-701.
22. Gomgnimbou MK, Abadia E, Zhang J, Refregier G, Panaiotov S, Bachiyska E, Sola C. 2012. "Spoligoriftyping," a dual-priming-oligonucleotide-based direct-hybridization assay for tuberculosis control with a multianalyte microbead- based hybridization system. J. Clin. Microbiol. 50:3172-3179.
23. Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D, Kuijper S, Bunschoten A, Molhuizen H, Shaw R, Goyal M, van Embden J. 1997. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J. Clin. Microbiol. 35: 907-914.
24. Morcillo N, Zumarraga M, Alito A, Dolmann A, Schouls L, Cataldi A, Kremer K, van Soolingen D. 2002. A low cost, home-made, reverse-line blot hybridisation assay for rapid detection of rifampicin resistance in Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 6:959-965.
25. van Soolingen D, Hermans PWM, de Haas PEW, Sool DR, van Embden JDA. 1991. The occurrence and stability of insertion sequences in Mycobacterium tuberculosis complex strains: evaluation of an insertion sequence- dependent DNA polymorphism as a tool in the epidemiology of tuberculosis. J. Clin. Microbiol. 29:2578-2586.
26. David H, Levy-Frebault V, Thorel MF. 1989. Méthodes de laboratoire pour Mycobactériologie clinique, p 1-87. Institut Pasteur, Paris, France.
27. Zhang J, Abadia E, Refregier G, Tafaj S, Boschiroli ML, Guillard B, Andremont A, Ruimy R, Sola C. 2010. Mycobacterium tuberculosis complex CRISPR genotyping: improving efficiency, throughput and discriminative power of 'spoligotyping' with new spacers and a microbead-based hybridization assay. J. Med. Microbiol. 59:285-294.
28. van Embden JDA, van Gorkom T, Kremer K, Jansen R, van der Zeijst BAM, Schouls LM. 2000. Genetic variation and evolutionary origin of the direct repeat locus of Mycobacterium tuberculosis complex bacteria. J. Bacteriol. 182:2393-2401.
29. Sebban M, Mokrousov I, Rastogi N, Sola C. 2002. A data-mining approach to spacer oligonucleotide typing of Mycobacterium tuberculosis. Bioinformatics 18:235-243.
30. Firdessa R, Berg S, Hailu E, Schelling E, Gumi B, Erenso G, Gadisa E, Kiros T, Habtamu M, Hussein J, Zinsstag J, Robertson BD, Ameni G, Lohan AJ, Loftus B, Comas I, Gagneux S, Tschopp R, Yamuah L, Hewinson G, Gordon SV, Young DB, Aseffa A. 2013. Mycobacterial lineages causing pulmonary and extrapulmonary tuberculosis, Ethiopia. Emerg. Infect. Dis. 19:460-463.
31. Bolotin S, Alexander DC, Chedore P, Drews SJ, Jamieson F. 2009. Molecular characterization of drug-resistant Mycobacterium tuberculosis isolates from Ontario, Canada. J. Antimicrob. Chemother. 64:263-266.
32. Sandgren A, Strong M, Muthukrishnan P, Weiner BK, Church GM, Murray MB. 2009. Tuberculosis drug resistance mutation database. PLoS Med. 6:e2. doi:10.1371/journal.pmed.1000002.
33. Bergval I, Sengstake S, Brankova N, Levterova V, Abadia E, Tadumaze N, Bablishvili N, Akhalaia M, Tuin K, Schuitema A, Panaiotov S, Bachiyska E, Kantardjiev T, de Zwaan R, Schurch A, van Soolingen D, van't Hoog A, Cobelens F, Aspindzelashvili R, Sola C, Klatser P, Anthony R. 2012. Combinedspecies identification, genotyping, and drug resistance detection of Mycobacterium tuberculosis cultures by MLPA on a bead-based array. PLoS One 7:e43240. doi:10.1371/journal.pone.0043240.
34. Coelho MB, Costa ER, Vasconcellos SE, Linck N, Ramos RM, Amorim HL, Suffys PN, Santos AR, Silva PE, Ramos DF, Silva MS, Rossetti ML. 2011. Sequence and structural characterization of tbnat gene in isoniazidresistant Mycobacterium tuberculosis: identification of new mutations. Mutat. Res. 712:33-39.
35. Lee JH, Ammerman NC, Nolan S, Geiman DE, Lun S, Guo H, Bishai WR. 2012. Isoniazid resistance without a loss of fitness in Mycobacterium tuberculosis. Nat. Commun. 3:753.
36. Payton M, Auty R, Delgoda R, Everett M, Sim E. 1999. Cloning and characterization of arylamine N-Acetyltransferase genes from Mycobacterium smegmatis and Mycobacterium tuberculosis: increased expression results in isoniazid resistance. J. Bacteriol. 181:1343-1347.
37. Ramos RM, Perez JM, Baptista LA, de Amorim HL. 2012. Interaction of wild type, G68R and L125M isoforms of the arylamine-Nacetyltransferase from Mycobacterium tuberculosis with isoniazid: a computational study on a new possible mechanism of resistance. J. Mol. Model. 18:4013-4024.
38. Niki M, Niki M, Tateishi Y, Ozeki Y, Kirikae T, Lewin A, Inoue Y, Matsumoto M, Dahl JL, Ogura H, Kobayashi K, Matsumoto S. 2012. A novel mechanism of growth phase-dependent tolerance to isoniazid in mycobacteria. J. Biol. Chem. 287:27743-27752.
39. Wang XD, Gu J, Wang T, Bi LJ, Zhang ZP, Cui ZQ, Wei HP, Deng JY, Zhang XE. 2011. Comparative analysis of mycobacterial NADH pyrophosphatase isoforms reveals a novel mechanism for isoniazid and ethionamide inactivation. Mol. Microbiol. 82:1375-1391.
40. Hauck Y, Fabre M, Vergnaud G, Soler C, Pourcel C. 2009. Comparison of two commercial assays for the characterization of rpoB mutations in Mycobacterium tuberculosis and description of new mutations conferring weak resistance to rifampicin. J. Antimicrob. Chemother. 64:259-262.
41. Zaczek A, Brzostek A, Augustynowicz-Kopec E, Zwolska Z, Dziadek J. 2009. Genetic evaluation of relationship between mutations in rpoB and resistance of Mycobacterium tuberculosis to rifampin. BMC Microbiol. 9:10.
42. Folkvardsen DB, Svensson E, Thomsen VO, Rasmussen EM, Bang D, Werngren J, Hoffner S, Hillemann D, Rigouts L. 2013. Can molecular methods detect 1% isoniazid resistance in Mycobacterium tuberculosis? J. Clin. Microbiol. 51:1596-1599.
43. Daum LT, Rodriguez JD, Worthy SA, Ismail NA, Omar SV, Dreyer AW, Fourie PB, Hoosen AA, Chambers JP, Fischer GW. 2012. Nextgeneration ion torrent sequencing of drug resistance mutations in Mycobacterium tuberculosis strains. J. Clin. Microbiol. 50:3831-3837.
44. Gomgnimbou MK, Refregier G, Diagbouga SP, Adama S, Kabore A, Ouiminga A, Sola C. 2012. Spoligotyping of Mycobacterium africanum, Burkina Faso. Emerg. Infect. Dis. 18:117-119.
45. Brudey K, Driscoll J, Rigouts L, Prodinger WM, Gori A, Al-Hajoj SAM, Allix C, Aristimuno L, Arora J, Baumanis V, Binder L, Cafrune P, Cataldi A, Cheong S, Diel R, Ellermeier C, Evans JT, Fauville-Dufaux M, Ferdinand S, Garcia de Viedma D, Garzelli C, Gazzola L, Gomes HM, Gutierrez MC, Hawkey PM, van Helden PD, Kadival GV, Kreiswirth BN, Kremer K, Kubin M, Kulkarni SP, Liens B, Lillebaek T, Ly HM, Martin C, Martin C, Mokrousov I, Narvskaia O, Ngeow YF, Naumann L, Niemann S, Parwati I, Rahim MZ, Rasolofo-Razanamparany V, Rasolonavalona T, Rossetti ML, Rüsch-Gerdes S, Sajduda A, Samper S, Shemyakin IG, Singh UB, Somoskovi A, Skuce R, Van Soolingen D, Streicher EM, Suffys PN, Tortoli E, Tracevska T, Vincent V, Victor TC, Warren R, Yap SF, Zaman K, Portaels F, Rastogi N, Sola C. 2006. Mycobacterium tuberculosis complex genetic diversity: mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics, and epidemiology. BMC Microbiol. 6:23.
46. Schnippel K, Rosen S, Shearer K, Martinson N, Long L, Sanne I, Variava E. 2013. Costs of inpatient treatment for multi-drug-resistant tuberculosis in South Africa. Trop. Med. Int. Health 18:109-116.